Product
vofatamab
1 clinical trial
14 indications
Indication
Advanced Solid TumorIndication
Head and Neck Squamous Cell CarcinomaIndication
Bladder CancerIndication
FGFR3 Genetic AlterationsIndication
FGFR3Indication
FGFR3 OverexpressionIndication
FGFR3 ReceptorIndication
FGFR3 Protein OverexpressionIndication
Ovarian CancerIndication
Colorectal CancerIndication
Breast CancerIndication
Liver CancerIndication
lung cancerIndication
Stomach CancerClinical trial
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid TumoursStatus: Terminated, Estimated PCD: 2023-09-08